Bal Pharma Ltd.
BSE Code: 524824
NSE Code: BALPHARMA
Last Close: Rs.22.90
Bal Pharma Ltd. (BPL) is a leading Indian pharmaceutical company specialising in prescription drugs, Generics, OTC products, Intravenous Infusion and Bulk Actives with 19 years of experience behind it. Successful operations in the domestic and global markets backed by its strengths in research and its strong infrastructure framework have accelerated BPL's growth from oblivion to US $25 million turnover today. Buoyed by this success, the group has put into motion fast track growth and has set its sight on sales in excess of US $150 million by 2012. The company has four manufacturing units - two in Bangalore, one in Pune and one in Uttarakhand. It has an equity base of Rs.10.45 cr. with huge reserves of around Rs.25 cr. Promoters hold 51.72% stake in the company while the investing public holds only 43.41%. BPL posted a net profit of Rs.3.91 cr. for the first 9 months of FY09 against Rs.2.85 cr. for full FY08. While we expect very good numbers for Q4FY09, the share price fell from Rs.35 to Rs.13 in one year and is currently available at Rs.21 at a P/E ratio of just 8. Buy at every decline with a stop loss of Rs.17. On the upper side, the stock will go up to Rs.27-29 level in the short-term and could go up to Rs.35 level in the medium-term.
Jagsonpal Pharma Ltd.
BSE Code: 507789
NSE Code: JAGSNPHARM
Last Close: Rs.14
Jagsonpal Pharma Ltd. (JPL) is among India's premier pharmaceutical companies. It has substantial R&D, manufacturing, marketing and distribution facilities. Founded in 1964, the company specialises in developing and manufacturing bulk drugs and pharmaceutical formulations. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation. The firm is represented by 2,500 agents worldwide and has offices in 3 continents. The company's operations span Russia, Brazil, USA, Ukraine, Sri Lanka, Cameroon, Thailand, Argentina, Germany, Switzerland, Korea, Egypt and Vietnam making its reach truly global. Its new plant at Uttarakhand commenced production in April 2008.
The company has an equity of Rs.13.09 cr. with huge reserves of around Rs.60 cr. The promoters hold 65.79% stake while the Indian public holds 26.09% stake. JPL posted a net profit of Rs.5.05 cr. in the first 9 months of FY09 against Rs.3.06 cr. for the whole of FY08. While we expect very good working numbers for the March 2009 quarter, its share price fell from Rs.18 to Rs.6 in just one year and is currently available at Rs.13 at a P/E ratio of just 6. Buy at every decline with a stop loss of Rs.10. On the upper side, the stock will go up to Rs.18-20 level in the short-term and it cold go up to Rs.25 level in the medium-term.
Source: Internet (moneytimes)
